CLSA: Maintains CTF SERVICES (00659) Target Price at HK$11.2 and "Outperform" Rating; Expects Special Dividend Within Next 12 Months
CLSA believes there is a high probability that CTF Services will announce a special dividend within the next 12 months, aimed at funding the Cheng family's participation in New World Development's rights issue.
CLSA issued a research report maintaining the target price of HK$11.2 and "Outperform" rating for CTF SERVICES (00659). The bank believes there is a high probability that CTF SERVICES will announce a special dividend within the next 12 months, aimed at funding the Cheng family's participation in the rights issue plan of NEW WORLD DEV (00017).
The bank noted that CTF SERVICES' sister company NEW WORLD DEV plans to conduct a "1-for-11" rights issue to raise a total of HK$24.9 billion. According to the latest disclosure documents from HKEX, the Cheng family, as the common controlling shareholder of both companies, currently holds 74.1% of CTF SERVICES and 45.3% of NEW WORLD DEV respectively. The family has made an irrevocable commitment to the aforementioned rights issue plan, confirming that it will participate in the rights issue.
Although there is no direct financial linkage between CTF SERVICES and NEW WORLD DEV, the bank believes there is a high probability that CTF SERVICES will announce a special dividend within the next 12 months. In late September, the Cheng family purchased 34.2 million CTF SERVICES shares in the open market, which the bank views as a signal that CTF SERVICES stock has investment value.
Related Articles

LUYE PHARMA (02186): Innovative Drug LY03021 Approved to Conduct Clinical Trial in the United States

CR CONSTRUCTION (01582) Clarification: CR Sea and the petitioner have not entered into any settlement agreement, and neither CR Sea nor the subcontractor has taken any steps to initiate proceedings to withdraw the petition.

HK Stock Market Move | PEIPORT HOLD (02885) surged over 24% to a new high as Hong Kong Lap completed the acquisition of 70% of its share capital and made an offer.
LUYE PHARMA (02186): Innovative Drug LY03021 Approved to Conduct Clinical Trial in the United States

CR CONSTRUCTION (01582) Clarification: CR Sea and the petitioner have not entered into any settlement agreement, and neither CR Sea nor the subcontractor has taken any steps to initiate proceedings to withdraw the petition.

HK Stock Market Move | PEIPORT HOLD (02885) surged over 24% to a new high as Hong Kong Lap completed the acquisition of 70% of its share capital and made an offer.






